Pfizer may take a hard look at a deal for Actavis; Ampio blames cold weather for trial delay;

@FierceBiotech: Lilly joins the list of Enbrel-beaters with head-to-head psoriasis showdown. News | Follow @FierceBiotech

@JohnCFierce: Global fear of Ebola outbreak stokes a frenzy of new R&D, production plans. More | Follow @JohnCFierce

@DamianFierce: ICYMI yesterday: $FOLD CEO on positive new migalastat data, next-gen Fabry treatment and the importance of perseverance. Report | Follow @DamianFierce

@EmilyMFierce: Parents more likely to vaccinate kids against measles when child's, not society's, benefits are stressed. FierceVaccines story | Follow @EmilyMFierce

> Spurned by AstraZeneca ($AZN) after making a $116 billion offer, Pfizer ($PFE) may be looking at other acquisitions that could get a coveted Irish tax domicile, including a possible deal for Actavis ($ACT). News

> Sarepta Therapeutics ($SRPT) has signed a deal with diagnostics outfit Flagship Biosciences to develop a test that can measure levels of the protein dystrophin, a key biomarker to determine whether patients with Duchenne muscular dystrophy are benefiting from treatment. Release

> Ampio Pharmaceuticals ($AMPE) said results from a Phase III study on its osteoarthritis drug will be delayed because the trial supplies of the treatment were exposed to extreme cold, news that sent its shares down more than 20%. More

> Auxlium Pharmaceuticals' ($AUXL) collagenase clostridium histolyticum met its main goals of improving the appearance of cellulite in a mid-stage trial. Item

Medical Device News

@FierceMedDev: ICYMI yesterday: NY Senators tell FDA to stop sales of power morcellators. Article | Follow @FierceMedDev

@VarunSaxena2: Russian scientists close in on drug-delivering nanorobots. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Chinese hackers infiltrate U.S. health care system as China's medical device industry booms. Bloomberg story | Follow @EmilyWFierce

> FDA allows Covidien to restart manufacturing of two recalled devices. Story

> FDA clarifies UDI requirements with new guidance. Story

> Baxter to invest $300M, hire 200 to expand hemodialysis manufacturing. Article

Pharma News

@FiercePharma: Top-read on FP Weds: Don't worry about a hep C pricing war, analysts tell Gilead-watchers. Article | Follow @FiercePharma

@TracyStaton: Been on vacay? @FiercePharma's top August news so far: Pfizer faces growing legal threat over Lipitor. Story | Follow @TracyStaton

@EricPFierce: FDA warning letter for India's Marck Biosciences lays out in vivid detail why it banned it plant. More | Follow @EricPFierce

@CarlyHFierce: @US_FDA approves first needle-free flu vaccine injection system. Story | Follow @CarlyHFierce

> Massive Novo insulin plant aims to make more with less. Story

> Pfizer eyes Actavis in backup plan to another AstraZeneca bid. Article

> Mylan, private equity, Indian pharmas to compete for cast-off GSK brands. More

Vaccines News

> Measles vaccination more likely when child's, not society's, benefits are stressed. Report

> Report: Takeda's dengue jab will be nipping at Sanofi's heels by 2020. More

> Chikungunya vaccine protects against virus in small Phase I study. Article

> FDA approves first needle-free flu vaccine injection system. More

> Clinical failure for Merck KGaA's cancer vaccine dents subpopulation hopes. Story

Pharma Manufacturing News

> Pfizer recalls nearly 94,000 vials of Depo-Medrol. Item

> Novo cutting emissions while building capacity at massive Denmark plant. Report

> Lonza gets a break on the tax break it got for the U.S. plant it is closing. More

> Hikma seizes on 'opportunities' for injectables growth. Article

> DOJ investigates Dr. Reddy's for failing to protect children with packaging. Story

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.